Adherence to Long-Term Therapies - Evidence for Action: Section III - Disease-Specific Reviews: Chapter IX

Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages)

Table of Contents

Preface
Acknowledgements
Scientific writers
Introduction
Take-home messages
Section I - Setting the scene
	Chapter I - Defining adherence
		1. What is adherence?
		2. The state-of-the-art measurement
		3. References
	Chapter II - The magnitude of the problem of poor adherence
		1. A worldwide problem of striking magnitude
		2. The impact of poor adherence grows as the burden of chronic diseases grows worldwide
		3. The poor are disproportionately affected
		4. References
	Chapter III - How does poor adherence affect policy-makers and health managers?
		1. Diabetes
		2. Hypertension
		3. Asthma
		4. References
Section II - Improving adherence rates: guidance for countries
	Chapter IV - Lessons learned
		1. Patients need to be supported, not blamed
		2. The consequences of poor adherence to long-term therapies are poor health outcomes and increased health care costs
		3. Improving adherence also enhances patient safety
		4. Adherence is an important modifier of health system effectiveness
		5. Improving adherence might be the best investment for tackling chronic conditions effectively
		6. Health systems must evolve to meet new challenges
		7. A multidisciplinary approach towards adherence is needed
		8. References
	Chapter V - Towards the solution
		1. Five interacting dimensions affect adherence
		2. Intervening in the five dimensions
		3. References
	Chapter VI - How can improved adherence be translated into health and economic benefits?
		1. Diabetes
		2. Hypertension
		3. Asthma
		4. References
Section III - Disease-Specific Reviews
	Chapter VII - Asthma
		1. Defining nonadherence to asthma therapy
		2. Rates of adherence to inhaled corticosteroids and other drugs for the prevention of asthma
		3. Forms of nonadherence
		4. Factors associated with adherence to asthma treatment
		5. Adherence in special populations
		6. Interventions to improve adherence to asthma therapy
		7. Discussion
		8. Conclusions
		9. References
	Chapter VIII - Cancer (Palliative care)
		1. Definitions and epidemiology of adherence
		2. Factors and interventions affecting adherence
		3. Conclusions
		4. References
	Chapter IX - Depression
		1. Research methods: measurement of adherence and sampling
		2. Rates of adherence
		3. Predictors of adherence
		4. Interventions to improve adherence
		5. Clinical implications and need for further research
		6. References
	Chapter X - Diabetes
		1. Introduction
		2. Treatment of diabetes
		3. Definition of adherence
		4. Prevalence of adherence to recommendations for diabetes treatment
		5. Correlates of adherence
		6. Interventions
		7. Methodological and conceptual issues in research on adherence to treatment for diabetes
		8. Conclusions
		9. References
	Chapter XI - Epilepsy
		1. Introduction
		2. Adherence to epilepsy therapy
		3. Epidemiology of adherence
		4. Factors affecting adherence and interventions used to improve it
		5. Conclusions
		6. References
	Chapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
		1. Types of nonadherence
		2. Challenges in assessing adherence
		3. Predictors of adherence
		4. A framework for interventions to increase adherence
		5. Conclusions
		6. References
	Chapter XIII - Hypertension
		1. Prevalence of adherence to pharmacotherapy in patients with hypertension
		2. Impact of adherence on blood pressure control and cardiovascular outcome
		3. Adherence to non-pharmacological treatment
		4. Factors contributing to adherence
		5. Interventions for improving adherence
		6. Conclusions
		7. References
	Chapter XIV - Tobacco smoking cessation
		1. The burden of tobacco smoking
		2. Clinical guidelines and therapies available for tobacco smoking cessation
		3. Definitions
		4. Epidemiology of adherence
		5. Factors affecting adherence
		6. Interventions for improving adherence
		7. Cost, effectiveness and cost-effectiveness of adherence
		8. Conclusions
		9. References
	Chapter XV - Tuberculosis
		1. Definition of adherence
		2. Factors that influence adherence to treatment
		3. Prediction of adherence
		4. Strategies to improve adherence to treatment
		5. Questions for future research
		6. References
Annexes
	Annex I - Behavioural mechanisms explaining adherence
		1. Introduction
		2. The nature of poor adherence
		3. Determinants of adherence
		4. Models
		5. Interventions
		6. Conclusions
		7. References
	Annex II - Statements by stakeholders
		1. Family, community and patients' organizations
		2. Behavioural medicine
		3. General practitioners/family physicians
		4. Industry
		5. Nurses
		6. Pharmacists
		7. Psychologists
	Annex III - Table of reported factors by condition and dimension
	Annex IV - Table of reported interventions by condition and dimension
	Annex V - Global Adherence Interdisciplinary Network (GAIN)
		Scientists
		Professional, industry and patients' organizations
		Policy-makers
Where to find a copy of this book
	Officially designated depository libraries for WHO publications
	Reference libraries for WHO publications
	WHO official sales agents world wide
	Selected WHO publications of related interest
	A ready-to-use pamphlet for partners willing to promote this book

6. References

1. Murray C, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990. Cambridge, MA, Harvard University Press, 1996.

2. Peveler R, Kendrick A. Treatment delivery and guidelines in primary care. British Medical Bulletin, 2001, 57: 193 - 206.

3. Kroll J et al. Medication compliance, antidepressant blood levels, and side effects in Southeast Asian patients. Journal of Clinical Psychopharmacology, 1990, 10: 279 - 283.

4. George CF et al. Compliance with tricyclic antidepressants: the value of four different methods of assessment. British Journal of Clinical Pharmacology, 2000, 50: 166 - 171.

5. Peveler R et al. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. British Medical Journal, 1999, 319: 612 - 615.

6. McCombs JS et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. Journal of Clinical Psychiatry, 1990, 51 (Suppl): 60 - 69.

7. Katon W et al. Adequacy and duration of antidepressant treatment in primary care. Medical Care, 1992, 30: 67 - 76.

8. Lin EH et al. Low-intensity treatment of depression in primary care: is it problematic? General Hospital Psychiatry, 2000, 22: 78 - 83.

9. Schumann C et al.; Nonadherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Research, 1999, 89: 247 - 257.

10. Ramana R et al. Medication received by patients with depression following the acute episode: adequacy and relation to outcome. British Journal of Psychiatry, 1999, 174: 128 - 134.

11. Gasquet I et al. [Determinants of compliance with antidepressive drugs.] [French] Encephale, 2001, 27: 83 - 91.

12. Myers ED, Branthwaite A. Out-patient compliance with antidepressant medication. British Journal of Psychiatry, 1992, 160: 83 - 86.

13. Claxton A et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. Journal of Clinical Psychiatry, 2000, 61: 928 - 932.

14. Lin EH et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Medical Care, 1995, 33: 67 - 74.

15. Tai-Seale M, Croghan TW, Obenchain R. Determinants of antidepressant treatment compliance: implications for policy. Medical Care Research & Review, 2000, 57: 491 - 512.

16. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology, 1995, 9 (Suppl 4): 33 - 40.

17. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal, 1995, 310: 1433 - 1438.

18. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry, 1997, 170: 120 - 127.

19. Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. Journal of Affective Disorders, 2001, 65: 173 - 177.

20. Keeley R, Smith M, Miller J. Somatoform symptoms and treatment nonadherence in depressed family medicine outpatients. Archives of Family Medicine, 2000, 9: 46 - 54.

21. Ekselius L, Bengtsson F, von Knorring L. Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality. International Clinical Psychopharmacology, 2000, 15: 273 - 278.

22. Tutty S, Simon G, Ludman E. Telephone counseling as an adjunct to antidepressant treatment in the primary care system. A pilot study. Effective Clinical Practice, 2000, 3: 170 - 178.

23. Mundt JC et al. Effectiveness of antidepressant pharmacotherapy: the impact of medication compliance and patient education. Depression & Anxiety, 2001, 13: 1 - 10.

24. Katon W et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. Journal of the American Medical Association, 1995, 273: 1026 - 1031.

25. Katon W et al. A multifaceted intervention to improve treatment of depression in primary care. Archives of General Psychiatry, 1996, 53: 924 - 932.

26. Lin EH et al. Can enhanced acute-phase treatment of depression improve long-term outcomes? A report of randomized trials in primary care. American Journal of Psychiatry, 1999, 156: 643 - 645.

27. Katon W et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Archives of General Psychiatry, 1999, 56: 1109 - 1115.

28. Katon W et al. A randomized trial of relapse prevention of depression in primary care. Archives of General Psychiatry, 2001, 58: 241 - 247.

29. Johnson, DA. Treatment of depression in general practice. 1973, British Medical Journal. 266: 18 - 20.